ASIT Biotech S. A., a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen rhinitis.

The company is also developing hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy. ASIT Biotech S. A. was incorporated in 1997 and is based in Liege, Belgium.

Address: 7 Rue des Chasseurs Ardennais, Liege, Belgium, 4031